Biopharmaceuticals - A Global Market Overview

Abstracts
Contents
About

The pharmaceutical R&D pipeline and industry have been witnessing greater degree of dependence on biopharmaceuticals. Development of these products is being undertaken by a growing number of players in the pharmaceutical industry, which include the big pharma companies as also generic drug manufacturers, who are also engaged in developing biosimilars. In conjunction with the traditional small biopharmaceutical companies, the new bigger entrants have been focused on continually expanding the global biologics pipeline, implying that the number and proportion of new pharmaceuticals being commercialized would increasingly comprise biopharmaceuticals and not small molecule drugs. As the cost of developing biopharmaceuticals and bringing them to market is generally much higher, offering enhanced profit margins, it comes as no surprise that the global pharmaceutical industry would continue to rely on biopharmaceuticals for profits and innovation, in addition to its very survival.

Even though the worldwide economic recession has been slow in recovering, the global pharmaceutical and biopharmaceutical industries have marched ahead, showing profitability and growth. According to estimates, more than 10k therapeutics are currently in the research and development stage, which include chemical substance pharmaceuticals or drugs and biotechnology-derived pharmaceuticals or biopharmaceuticals undergoing over 40k clinical trials. This translates into a significant increase from as little as half-a-decade back, indicating a conspicuous shift in the pharmaceutical industry from developing small molecule drugs to biopharmaceuticals for obtaining novel, ground-breaking and profitable solutions.

The report reviews, analyses and projects the biopharmaceuticals market (2010-2020) for global and the regional markets including North America, Europe, Asia-Pacific, South America and Rest of World. The regional markets further analyzed for 14 independent countries across North America – The United States, Canada and Mexico; Europe – Germany, the United Kingdom, France, Italy, Spain and Russia; Asia-Pacific – Japan, China and India; South America – Argentina and Brazil.

Biopharmaceuticals product segments analyzed in this study comprises Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and others. Therapeutic areas analyzed include Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and others. Biopharmaceuticals market, estimated at US$199.7 billion globally in 2013, is further projected to reach US$497.9 billion by 2020, growing at 13.5% CAGR between 2010 and 2020. Among different product segments, monoclonal antibodies (moAb) constitutes the largest product segment in the global biopharmaceuticals market accounting for an estimated share of 25.6% in 2013, equating to US$51.1 billion. In terms of therapeutic area, neurology applications is the largest market for global biopharmaceuticals with an estimated 2013 share of 28.2% valued at US$56.3 billion, and further expected reach a projected US$144.5 billion by 2020.

The study includes 249 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the global market by geographic region, product segment and therapeutic area. This study profiles 25 key global players and 70 major players across North America – 24; Europe – 17; Asia-Pacific – 27 and Rest of World – 2. The report also provides the listing of the companies engaged in research and development, manufacturing and supply of biopharmaceuticals. The global list of companies covers addresses, contact numbers and the website addresses of 492 companies.

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Evolution of the Industry
1.2 Product Outline
  1.2.1 What are biopharmaceuticals?
    1.2.1.1 Description of Biopharmaceuticals
    1.2.1.2 Commercialization of Biopharmaceuticals
    1.2.1.3 Regulation of Biopharmaceuticals
    1.2.1.4 Principal Categories of Biopharmaceuticals and their Uses
    1.2.1.5 Large Scale Production of Biopharmaceuticals
      1.2.1.5.1 Transgenic
  1.2.2 Categorization of Biopharmaceuticals
    1.2.2.1 Monoclonal Antibodies
      1.2.2.1.1 Production of Monoclonal Antibodies
      1.2.2.1.2 Primary Applications of Monoclonal Antibodies
      1.2.2.1.3 Anti-Inflammatory Monoclonal Antibodies
      1.2.2.1.4 Anti-Cancer Monoclonal Antibodies
      1.2.2.1.5 Other Monoclonal Antibodies
      1.2.2.1.6 Therapeutic Applications of Monoclonal Antibodies
      1.2.2.1.7 Therapeutic Monoclonal Antibodies Approved by the FDA
    1.2.2.2 Erythropoietin (EPO)
      1.2.2.2.1 Functions of EPO
      1.2.2.2.2 Medical Uses of EPO
        1.2.2.2.2.1 Available Forms of EPO
    1.2.2.3 Biotech Vaccines
      1.2.2.3.1 Categories of Vaccines
      1.2.2.3.2 Recombinant Vector Vaccines
      1.2.2.3.3 Production of Recombinant Vector Vaccines
      1.2.2.3.4 Positives and Negatives of Recombinant Vector Vaccines
    1.2.2.4 Recombinant Human (RH) Insulin
      1.2.2.4.1 Production of RH Insulin
    1.2.2.5 Granulocyte Colony-Stimulating Factor (G-CSF)
      1.2.2.5.1 Biological Role of G-CSF
      1.2.2.5.2 Therapeutic Applications of G-CSF
      1.2.2.5.3 Some Highlights of G-CSF
    1.2.2.6 Interferons (IFNs)
      1.2.2.6.1 Types of Interferons
      1.2.2.6.2 Functions of Interferons
      1.2.2.6.3 Disease Therapy with Interferons
      1.2.2.6.4 Interferons and Drug Formulations
    1.2.2.7 Human Growth Hormones
      1.2.2.7.1 The Functioning of Human Growth Hormone
      1.2.2.7.2 Clinical Importance of HGH
      1.2.2.7.3 Use of HGH as a Medication
    1.2.2.8 Other Biopharmaceuticals
      1.2.2.8.1 Blood Factors (Factor VIII and Factor IX)
        1.2.2.8.1.1 Factor VIII
        1.2.2.8.1.2 Factor IX
      1.2.2.8.2 Thrombolytic Agents (Tissue Plasminogen Activator)
      1.2.2.8.3 Interleukin-Based Products
        1.2.2.8.3.1 Human Interleukins
      1.2.2.8.4 Tumor Necrosis Factor
      1.2.2.8.5 Therapeutic Enzymes

2. KEY FACTS AND FIGURES OF BIOPHARMA INDUSTRY AND LATEST APPROVALS

2.1 Some Key Facts about the Biopharmaceutical Industry
2.2 Biopharmaceuticals Approved by the USFDA in 2012 and 2013 (To Date)

3. KEY MARKET TRENDS

3.1 Enhancing Industry Health and Standing
3.2 Spending and Investment in Biopharmaceuticals Rising
3.3 Shifts in Outsourcing Trends
3.4 Continuing but Slowing Mega M&A Activity with More Emphasis on Strategy
3.5 New and Small Companies Feeling the Pinch
3.6 Can “BRICS” Build Up the Biopharmaceutical Industry?
3.7 What Ails the Biopharmaceutical Product Pipeline?
3.8 R&D in Biopharmaceuticals Surpassing Drug R&D
3.9 Biopharmaceutical Companies Going Global
3.10 Developing Countries Forging Ahead with Biopharmaceutical Manufacturing
3.11 Manufacturing Processes Attaining Global Standardization
3.12 In Conclusion

4. KEY GLOBAL PLAYERS

Abbott Laboratories, Inc.
Amgen, Inc.
Astrazeneca PLC
BASF SE
Bayer AG
Biocon Ltd.
Biogen Idec
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company Limited
Eli Lilly and Company
Genentech, Inc.
Glaxosmithkline, PLC
Hospira, Inc.
Johnson & Johnson, Inc.
LG Life Sciences
Novartis AG
Novo Nordisk A/S
Pfizer, Inc.
Ranbaxy Laboratories Ltd.
Roche Holding AG
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
UCB S.A

5. KEY BUSINESS TRENDS

Completion of Inspiration's Hemophilia Products Sale
Novozymes Biopharma and EpiVax Ink Research Agreement
Glenmark Pharmaceuticals SA Discovers and Initiates IND Studies for GBR
Navidea Establishes Strategic Alliance with Maimonides Medical Center
Bayer and Regeneron Kickoffs VEGF Trap-Eye Phase III Trial to Treat DME
Novartis Kickoffs Biopharmaceutical Unit Construction
Roche Partners Chiasma on Octreolin Development and Commercialization
Partnership between Refine Technology and Gallus BioPharmaceuticals for Continuous Cell Culture Processing
Navidea Biopharmaceuticals Completes NAV4694's Clinical Trial
GVK Biosciences Inks Collaboration with Onconova therapeutics on Novel Cancer Drugs
Completion of Abbott's Research-based Pharmaceuticals Business Spin-off Forms AbbVie
Bio-Rad Launches 2-DE/WB workflow for Anti-HCP Antibodies Assessment
Novozymes biopharma Unveils New Brand for its rAlbumin Product Line
Expansion of Cytovance Biologics' mammalian production capabilities in 2013
GlaxoSmithKline Partners with Biological E. for Combination Vaccine Development
Baxter Takes Over Inspiration's OBI-1 Assets
BASF Acquires Pronova BioPharma
Sutro Biopharma and Sanofi Pasteur form Alliance on Vaccine Production
Development of Pertussis mAb therapies Started by Synthetic Biologics and Intrexon Corporation
Teva Pharmaceuticals Establishes Strategic Alliance with Galena Biopharma on NeuVax
FDA Approves MycoTOOL PCR Mycoplasma Detection Kit of Roche
Boehringer Inks Manufacturing Supply Agreement with Apexigen for Cancer mAbs
Merck Signs Agreement with GE Healthcare to Use [18F] Flutemetamol for the Development of
MK-8931, BACE Inhibitor for AD
Galena Biopharma Collaborates with Leica Biosystems for HER2 Companion Diagnostic Development
ProMetic Life Sciences in Collaboration with NantPharma Develop Second Plasma-derived Biopharmaceutical
Pamorelin LA of Debiopharm Unveiled by Dr. Reddy's in India to Treat Prostate Cancer
Inspiration's OBI-1 for Acquired Hemophilia A Receives FDA's Fast Track Designation
New Licensed Biopharmaceuticals Produced by Fujifilm Diosynth Biotechnologies
PAREXEL Establishes a Strategic Alliance with National Taiwan University Hospital
SAFC Broadens the line of PharmaGrade Raw Materials for Biopharmaceutical Production
ActoGeniX and Merck Form Research Pact
Sandoz Biopharmaceuticals Inaugurates Cellular and Molecular Biology Laboratory in Menges
Boehringer Ingelheim Introduces Smart-to-Launch Fast Track Project Transfer Process
Launch of Biopharmaceutical Contract Manufacturing Offering by Olympus Biotech
SAFC Establishes Strategic Alliance with CrystalGenomics
Global Phase 3 Study for Recombinant Human Insulin of Biocon Achieves Positive Outcome
Fujifilm Diosynth Partners with Piramal Healthcare in ADCs Contract Manufacturing
DSM Collaborates with Paranta Biosciences
Wacker Biotech Partners with XL-protein for PASylated Therapeutic Proteins Production
Implementation of Boehringer Ingelheim's Flexible Biopharmaceutical Disposable Set-up
KUBio, Modular Biopharmaceutical Factory Inaugurated by GE Healthcare
Synthetic Biologics Kickoffs the Development of mAbs to Treat Acinetobacter Infections
Gallus BioPharmaceuticals Establishes Strategic Alliance with Roslin Cells for Cell Therapeutics' Supply
Constellation Pharmaceuticals Forms Strategic Alliance with The Leukemia & Lymphoma Society on BET Inhibitor Development
Evotec AG Inks Collaboration with Aspireo
Boehringer Ingelheim Inks Collaboration with Servier and XOMA
Biochrom AG Acquired by Merck KGaA
Gallus BioPharmaceuticals Partners with Natrix Separations Inc.
Collaboration between Theorem Clinical Research and Gallus BioPharmaceuticals
GE Healthcare Establishes Strategic Alliance with iBio for Using Plant-based Technologies in Biopharmaceuticals Production
Daiichi Sankyo Plans to Initiate Japanese Ministry's Biopharmaceuticals Unit Construction
Inspiration Biopharmaceuticals Places its Two IB1001 Clinical Trials on Hold
ProMetic Life Sciences Inks Collaboration with NantPharma for Plasma-derived Biopharmaceutical Development
Unveiling Bristol-Myers Squibb's Coverage with US$35 Trefis Price Estimate
Saint-Gobain Introduces C-Flex ULTRA Pump Tubing Excelling the Competition
Launch of Boehringer Ingelheim's Typical Brand Boehringer Ingelheim BioXcellence
Merck KGaA Establishes Alliance with Dr Reddy's to Develop Biosimilar mAbs
Strategic Alliance of DSM to Offer Contract Manufacturing Services
Bharat Biotech and University of Maryland to Collaborate on iNTS Vaccine Development
Collaboration between Daiichi Sankyo and Coherus BioSciences on Biosimilars
Grace and Formac Pharmaceuticals Completes Silica-Based Drug Delivery Technology's Clinical Trial
Celltrion Steps into CMO Business for Novel Drugs Production in Korea
Research Organics Acquired by Sigma-Aldrich
Introduction of Lean-to-Clinic Program by Boehringer Ingelheim
GE Healthcare Acquires Xcellerex to Spread out its Competences in the Emerging Biopharmaceutical Industry
Daiichi Sankyo Signs Research Collaboration and License Agreement with NGM
GE Healthcare Plans to Acquire Xcellerex to Enhance Biopharma Potencies
Expansion of Boehringer Ingelheim's Biopharmaceutical Process Science Capabilities
Morria Biopharmaceuticals and Scynexis form Alliance to Sustain MRX-4 Activities
Boehringer Ingelheim Establishes Strategic Alliance with Xencor to Develop, Produce and Commercialize Biosuperior mAbs
Sigma-Aldrich Acquires BioReliance to Advance Biopharmaceuticals Production
Sigma-Aldrich Plans BioReliance Acquisition to Offer Biopharmaceutical Testing and Services
Bristol-Myers Squibb Marks Merger Agreement with Inhibitex
Initiation of Hospira's Biosimilar EPO Phase III Clinical Trial in US
Strategic Alliance between GE Healthcare and M+W Group
Lonza Unveils pDNA Production Platform to Produce Microbial Biopharmaceuticals
Repligen Acquires Novozymes Biopharma Sweden AB
Simcere Inks Collaboration with Bristol-Myers Squibb for Developing BMS-795311
Novozymes Biopharma Partners with R-Tech Ueno to Supply Albucult
Inspiration Biopharmaceuticals starts the Second OBI-1's Accur8 Clinical Trial
ASLAN Pharmaceuticals and Bristol-Myers Squibb form BMS-777607 Development Pact
Fujifilm Diosynth Biotechnologies Partners with ContraFect Corporation to Develop and Manufacture CF-301
Bayer HealthCare Restructure Collaboration with Onyx Pharmaceuticals
Boehringer Ingelheim Receives Frost & Sullivan Award for Biopharmaceutical Contract Manufacturing
Biocon Heralds Project Initiation to Establish Biopharmaceutical Manufacturing and R&D Unit in Bio-XCell
CMC Biologics and Inspiration Biopharmaceuticals Collaborate on IB1001 Manufacture
Expansion of Boehringer Ingelheim's Fill and Finish Competences for Biopharmaceuticals
Introduction of BD Recharge by BD Biosciences to Augment Biopharmaceutical Protein Production
Fujifilm Partners with Mitsubishi in Biopharmaceutical Contract Manufacturing
Expansion of Fujifilm Diosynth Biotechnologies' Mammalian Cell Culture Capacity
Xcellerex Inks Collaboration with Gallus BioPharmaceuticals
Strategic License Agreement between Sanofi and Glenmark Pharmaceuticals on GBR500
Inauguration of EMD Millipore's Biopharmaceutical Technical Center in Shanghai
Novozymes Biopharma Launches Albufuse Flex Technology Developed by Joining Forces with the University of Oslo
Amgen's Biopharmaceutical Development and Manufacturing Unit Acquired by Boehringer Ingelheim
Unveiling of All-in-one Chromatography System of Bio-Rad
Forest Laboratories and Allergy Asthma Research Institute Fall in SAFE-BioPharma Association
Ipsen Establishes Strategic alliance with bioMйrieux in Theranostics
Inspiration Biopharmaceuticals Demonstrates Non-inferiority of IB1001

6. GLOBAL MARKET OVERVIEW

6.1 Global Market by Product Segment
  6.1.1 Biopharmaceutical Product Market Overview by Global Region
    6.1.1.1 Monoclonal Antibodies (moAb)
    6.1.1.2 Erythropoietin
    6.1.1.3 Biotech Vaccines
    6.1.1.4 Recombinant Human (RH) Insulin
    6.1.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
    6.1.1.6 Interferons
    6.1.1.7 Human Growth Hormones (HGH)
    6.1.1.8 Other Biopharmaceuticals
6.2 Global Market by Therapeutic Area
  6.2.1 Biopharmaceutical Therapeutic Area Market Overview by Global Region
    6.2.1.1 Neurology
    6.2.1.2 Infectious Diseases
    6.2.1.3 Diabetes
    6.2.1.4 Oncology
    6.2.1.5 Cardiovascular
    6.2.1.6 Other Therapeutic Areas

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

1. NORTH AMERICA

1.1 North American Biopharmaceutical Market by Geographic Region
1.2 North American Biopharmaceutical Market by Product Segment
  1.2.1 Biopharmaceutical Product Market Overview by North American Region
    1.2.1.1 Monoclonal Antibodies (moAb)
    1.2.1.2 Erythropoietin
    1.2.1.3 Biotech Vaccines
    1.2.1.4 Recombinant Human (RH) Insulin
    1.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
    1.2.1.6 Interferons
    1.2.1.7 Human Growth Hormones (HGH)
    1.2.1.8 Other Biopharmaceuticals
1.3 North American Biopharmaceutical Market by Therapeutic Area
  1.3.1 Biopharmaceutical Therapeutic Area Market Overview by North American Region
    1.3.1.1 Neurology
    1.3.1.2 Infectious Diseases
    1.3.1.3 Diabetes
    1.3.1.4 Oncology
    1.3.1.5 Cardiovascular
    1.3.1.6 Other Therapeutic Areas
1.4 Major Market Players
  Abbott Laboratories, Inc.
  Alder Biopharmaceuticals Inc.
  Alexion Pharmaceuticals, Inc
  Amgen, Inc.
  Analytical Biological Services Inc
  Array Biopharma Inc.
  Atlanta Biologicals, Inc
  Baxter Bioscience Inc
  Biogen Idec
  Bristol-Myers Squibb Company
  Charles River Laboratories International, Inc.
  Eli Lilly and Company
  Fujifilm Diosynth Biotechnologies
  Genentech, Inc.
  Genzyme Corporation
  Hospira, Inc.
  Johnson & Johnson
  Millennium Pharmaceuticals, Inc.
  Novozymes Biopharma US, Inc.
  Onyx Pharmaceuticals, Inc.
  Pfizer Inc
  Seattle Genetics, Inc
  Soligenix, Inc.
  Teva North America
1.5 North American Biopharmaceutical Market Overview by Country
  1.5.1 THE UNITED STATES
    1.5.1.1 Biopharmaceutical Market by Product Segment
    1.5.1.2 Biopharmaceutical Market by Therapeutic Area
  1.5.2 CANADA
    1.5.2.1 Biopharmaceutical Market by Product Segment
    1.5.2.2 Biopharmaceutical Market by Therapeutic Area
  1.5.3 MEXICO
    1.5.3.1 Biopharmaceutical Market by Product Segment
    1.5.3.2 Biopharmaceutical Market by Therapeutic Area

2. EUROPE

2.1 European Biopharmaceutical Market by Geographic Region
2.2 European Biopharmaceutical Market by Product Segment
  2.2.1 Biopharmaceutical Product Market Overview by European Region
    2.2.1.1 Monoclonal Antibodies (moAb)
    2.2.1.2 Erythropoietin
    2.2.1.3 Biotech Vaccines
    2.2.1.4 Recombinant Human (RH) Insulin
    2.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
    2.2.1.6 Interferons
    2.2.1.7 Human Growth Hormones (HGH)
    2.2.1.8 Other Biopharmaceuticals
2.3 European Biopharmaceutical Market by Therapeutic Area
  2.3.1 Biopharmaceutical Therapeutic Area Market Overview by European Region
    2.3.1.1 Neurology
    2.3.1.2 Infectious Diseases
    2.3.1.3 Diabetes
    2.3.1.4 Oncology
    2.3.1.5 Cardiovascular
    2.3.1.6 Other Therapeutic Areas
2.4 Major Market Players
  3P Biopharmaceuticals S.L. (Spain)
  Applikon Biotechnology B.V. (The Netherlands)
  Astrazeneca Plc (United Kingdom)
  BASF SE (Germany)
  Bayer AG (Germany)
  Boehringer Ingelheim GmbH (Germany)
  Cellgenix GmbH (Germany)
  Evotec AG (Germany)
  Glaxosmithkline, PLC (United Kingdom)
  Merck Serono S.A. (Switzerland)
  Novartis AG (Switzerland)
  Novo Nordisk A/S (Denmark)
  Novozymes A/S (Denmark)
  Pronova Biopharma ASA (Norway)
  Roche Holding AG (Switzerland)
  Sanofi (France)
  UCB S.A. (Belgium)
2.5 European Biopharmaceutical Market Overview by Country
  2.5.1 GERMANY
    2.5.1.1 Biopharmaceutical Market by Product Segment
    2.5.1.2 Biopharmaceutical Market by Therapeutic Area
  2.5.2 THE UNITED KINGDOM
    2.5.2.1 Biopharmaceutical Market by Product Segment
    2.5.2.2 Biopharmaceutical Market by Therapeutic Area
  2.5.3 FRANCE
    2.5.3.1 Biopharmaceutical Market by Product Segment
    2.5.3.2 Biopharmaceutical Market by Therapeutic Area
  2.5.4 ITALY
    2.5.4.1 Biopharmaceutical Market by Product Segment
    2.5.4.2 Biopharmaceutical Market by Therapeutic Area
  2.5.5 SPAIN
    2.5.5.1 Biopharmaceutical Market by Product Segment
    2.5.5.2 Biopharmaceutical Market by Therapeutic Area
  2.5.6 RUSSIA
    2.5.6.1 Biopharmaceutical Market by Product Segment
    2.5.6.2 Biopharmaceutical Market by Therapeutic Area
  2.5.7 REST OF EUROPE
    2.5.7.1 Biopharmaceutical Market by Product Segment
    2.5.7.2 Biopharmaceutical Market by Therapeutic Area

3. ASIA-PACIFIC

3.1 Asia-Pacific Biopharmaceuticals Market by Geographic Region
3.2 Asia-Pacific Biopharmaceuticals Market by Product Segment
  3.2.1 Biopharmaceutical Product Market Overview by Asia-Pacific Region
    3.2.1.1 Monoclonal Antibodies (moAb)
    3.2.1.2 Erythropoietin
    3.2.1.3 Biotech Vaccines
    3.2.1.4 Recombinant Human (RH) Insulin
    3.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
    3.2.1.6 Interferons
    3.2.1.7 Human Growth Hormones (HGH)
    3.2.1.8 Other Biopharmaceuticals
3.3 Asia-Pacific Biopharmaceuticals Market by Therapeutic Area
  3.3.1 Biopharmaceutical Therapeutic Area Market Overview by Asia-Pacific Region
    3.3.1.1 Neurology
    3.3.1.2 Infectious Diseases
    3.3.1.3 Diabetes
    3.3.1.4 Oncology
    3.3.1.5 Cardiovascular
    3.3.1.6 Other Therapeutic Areas
3.4 Major Market Players
  Aurobindo Pharma Ltd. (India)
  Beijing Sl Pharmaceutical Co Ltd (China)
  Beijing Tiantan Biological Products Co Ltd (China)
  Biocon Ltd. (India)
  Biological E Limited (India)
  Bukwang Pharmaceutical Co Ltd (South Korea)
  Cadila Healthcare Limited (Zydus Cadila) (India)
  Celltrion, Inc. (South Korea)
  Cipla Ltd (India)
  Daiichi Sankyo Company Limited (Japan)
  Dainippon Sumitomo Pharma Co Ltd (Japan)
  Glenmark Pharmaceuticals Limited (India)
  GVK Biosciences Pvt Ltd (India)
  Hualan Biological Engineering Inc (China)
  LG Life Sciences (South Korea)
  Ranbaxy Laboratories Ltd. (India)
  RPG Life Sciences Limited (India)
  Reliance Life Sciences Pvt Ltd (India)
  Samsung Biologics Co Ltd (South Korea)
  Sanofi India Limited (India)
  SciGen Ltd. (Singapore)
  Shanghai Institute of Biological Products (China)
  Shantha Biotechnics Ltd (India)
  Sun Pharmaceutical Industries Ltd (India)
  Suven Life Sciences Ltd (India)
  Takeda Pharmaceutical Company Limited (Japan)
  Torrent Pharmaceuticals Limited (India)
3.5 Asia-Pacific Biopharmaceuticals Market by Country
  3.5.1 JAPAN
    3.5.1.1 Biopharmaceuticals Market by Product Segment
    3.5.1.2 Biopharmaceuticals Market by Therapeutic Area
  3.5.2 CHINA
    3.5.2.1 Biopharmaceuticals Market by Product Segment
    3.5.2.2 Biopharmaceuticals Market by Therapeutic Area
  3.5.3 INDIA
    3.5.3.1 Biopharmaceuticals Market by Product Segment
    3.5.3.2 Biopharmaceuticals Market by Therapeutic Area
  3.5.4 REST OF ASIA-PACIFIC
    3.5.4.1 Biopharmaceuticals Market by Product Segment
    3.5.4.2 Biopharmaceuticals Market by Therapeutic Area

4. SOUTH AMERICA

4.1 South American Biopharmaceuticals Market by Geographic Region
4.2 South American Biopharmaceuticals Market by Product Segment
  4.2.1 Biopharmaceutical Product Market Overview by South American Region
    4.2.1.1 Monoclonal Antibodies (moAb)
    4.2.1.2 Erythropoietin
    4.2.1.3 Biotech Vaccines
    4.2.1.4 Recombinant Human (RH) Insulin
    4.2.1.5 Granulocyte Colony-Stimulating Factor (G-CSF)
    4.2.1.6 Interferons
    4.2.1.7 Human Growth Hormones (HGH)
    4.2.1.8 Other Biopharmaceuticals
4.3 South American Biopharmaceuticals Market by Therapeutic Area
  4.3.1 Biopharmaceutical Therapeutic Area Market Overview by South American Region
    4.3.1.1 Neurology
    4.3.1.2 Infectious Diseases
    4.3.1.3 Diabetes
    4.3.1.4 Oncology
    4.3.1.5 Cardiovascular
    4.3.1.6 Other Therapeutic Areas
4.4 South American Biopharmaceutical Market by Country
  4.4.1 ARGENTINA
    4.4.1.1 Biopharmaceutical Market by Product Segment
    4.4.1.2 Biopharmaceutical Market by Therapeutic Area
  4.4.2 BRAZIL
    4.4.2.1 Biopharmaceutical Market by Product Segment
    4.4.2.2 Biopharmaceutical Market by Therapeutic Area
  4.4.3 REST OF SOUTH AMERICA
    4.4.3.1 Biopharmaceutical Market by Product Segment
    4.4.3.2 Biopharmaceutical Market by Therapeutic Area

5. REST OF WORLD

5.1 Rest of World Biopharmaceutical Market by Product Segment
5.2 Rest of World Biopharmaceutical Market by Therapeutic Area
5.3 Major Market Players
  D-Pharm Ltd. (Israel)
  Teva Pharmaceutical Industries Ltd. (Israel)

PART C: GUIDE TO THE INDUSTRY

1. NORTH AMERICA

1.1 Canada
1.2 United States

2. EUROPE

2.1 Austria
2.2 Belgium
2.3 Denmark
2.4 France
2.5 Germany
2.6 Ireland
2.7 Lithuania
2.8 Norway
2.9 Spain
2.10 Sweden
2.11 Switzerland
2.12 The Netherlands
2.13 United Kingdom

3. ASIA-PACIFIC

3.1 Australia
3.2 China
3.3 Hong Kong
3.4 India
3.5 Indonesia
3.6 Japan
3.7 Malaysia
3.8 Singapore
3.9 South Korea
3.10 Taiwan

4. REST OF WORLD

4.1 Brazil
4.2 Israel

PART D: ANNEXURE

1. RESEARCH METHODOLOGY

2. THE QUESTIONNAIRE

3. FEEDBACK

CHARTS & GRAPHS

PART A: GLOBAL MARKET PERSPECTIVE
Chart 1: Evolution of Biopharma Industry in Past Decade (2004-2013)
Chart 2: The FDA Approved Monoclonal Antibodies – Antibody, Brand, Company, Mechanism of Action and Indication
Chart 3: Forms of EPO – EPO Form, Drug Name and Manufacturer
Chart 4: Types of Human Interferons based on Type of Receptor Used in Signaling – Interferon Type I, Interferon Type II and Interferon Type III
Chart 5: The List of Interleukins (IL-1 to IL 36) – Interleukin Name, Source, Target Receptors, Target Cells and Function
Chart 6: Global Biopharmaceuticals Market Analysis (2010-2020) in US$ Million
Chart 7: Global Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 8: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 9: Global Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 10: Glance at 2010, 2015 and 2020 Global Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 11: Global Erythropoietin Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 12: Glance at 2010, 2015 and 2020 Global Erythropoietin Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 13: Global Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 14: Glance at 2010, 2015 and 2020 Global Biotech Vaccines Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 15: Global Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 16: Glance at 2010, 2015 and 2020 Global Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 17: Global Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 18: Glance at 2010, 2015 and 2020 Global Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 19: Global Interferons Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 20: Glance at 2010, 2015 and 2020 Global Interferons Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 21: Global Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 22: Glance at 2010, 2015 and 2020 Global Human Growth Hormones (HGH) Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 23: Global Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 24: Glance at 2010, 2015 and 2020 Global Other Biopharmaceuticals Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 25: Global Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 26: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas
Chart 27: Global Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 28: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 29: Global Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 30: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 31: Global Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 32: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 33: Global Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 34: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 35: Global Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 36: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World
Chart 37: Global Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World in US$ Million
Chart 38: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – North America, Europe, Asia-Pacific, South America and Rest of World

PART B: REGIONAL MARKET PERSPECTIVE
Chart 39: The Projection of Prospective Regions in terms of Market Growth for Biopharmaceuticals by Geography – Asia-Pacific, South America, Europe and North America
Chart 40: Global Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – North America, Europe, Asia–Pacific, South America and Rest of World in US$ Million
Chart 41: Glance at 2010, 2015 and 2020 Global Biopharmaceuticals Market Share (%) by Geographic Region – North America, Europe, Asia–Pacific, South America and Rest of World

NORTH AMERICA
Chart 42: North American Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 43: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 44: North American Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 45: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 46: North American Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 47: Glance at 2010, 2015 and 2020 North American Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 48: North American Erythropoietin Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 49: Glance at 2010, 2015 and 2020 North American Erythropoietin Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 50: North American Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 51: Glance at 2010, 2015 and 2020 North American Biotech Vaccines Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 52: North American Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 53: Glance at 2010, 2015 and 2020 North American Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 54: North American Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 55: Glance at 2010, 2015 and 2020 North American Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 56: North American Interferons Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 57: Glance at 2010, 2015 and 2020 North American Interferons Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 58: North American Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 59: Glance at 2010, 2015 and 2020 North American Human Growth Hormones (HGH) Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 60: North American Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 61: Glance at 2010, 2015 and 2020 North American Other Biopharmaceuticals Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 62: North American Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 63: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas
Chart 64: North American Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 65: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – United States, Canada and Mexico
Chart 66: North American Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 67: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 68: North American Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 69: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 70: North American Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 71: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 72: North American Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 73: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – United States, Canada and Mexico
Chart 74: North American Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – United States, Canada and Mexico in US$ Million
Chart 75: Glance at 2010, 2015 and 2020 North American Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – United States, Canada and Mexico

THE UNITED STATES
Chart 76: United States Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 77: Glance at 2010, 2015 and 2020 United States Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 78: United States Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 79: Glance at 2010, 2015 and 2020 United States Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

CANADA
Chart 80: Canadian Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 81: Glance at 2010, 2015 and 2020 Canadian Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 82: Canadian Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 83: Glance at 2010, 2015 and 2020 Canadian Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

MEXICO
Chart 84: Mexican Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 85: Glance at 2010, 2015 and 2020 Mexican Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 86: Mexican Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 87: Glance at 2010, 2015 and 2020 Mexican Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

EUROPE
Chart 88: European Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 89: Glance at 2010, 2015 and 2020 European Biopharmaceuticals Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 90: European Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 91: Glance at 2010, 2015 and 2020 European Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 92: European Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 93: Glance at 2010, 2015 and 2020 European Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 94: European Erythropoietin Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 95: Glance at 2010, 2015 and 2020 European Erythropoietin Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 96: European Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 97: Glance at 2010, 2015 and 2020 European Biotech Vaccines Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 98: European Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 99: Glance at 2010, 2015 and 2020 European Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 100: European Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 101: Glance at 2010, 2015 and 2020 European Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 102: European Interferons Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 103: Glance at 2010, 2015 and 2020 European Interferons Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 104: European Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 105: Glance at 2010, 2015 and 2020 European Human Growth Hormones (HGH) Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 106: European Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 107: Glance at 2010, 2015 and 2020 European Other Biopharmaceuticals Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 108: European Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 109: Glance at 2010, 2015 and 2020 European Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas
Chart 110: European Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 111: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 112: European Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 113: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 114: European Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 115: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 116: European Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 117: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 118: European Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 119: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe
Chart 120: European Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe in US$ Million
Chart 121: Glance at 2010, 2015 and 2020 European Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – Germany, United Kingdom, France, Italy, Spain, Russia and Rest of Europe

GERMANY
Chart 122: German Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 123: Glance at 2010, 2015 and 2020 German Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 124: German Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 125: Glance at 2010, 2015 and 2020 German Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

THE UNITED KINGDOM
Chart 126: United Kingdom Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 127: Glance at 2010, 2015 and 2020 United Kingdom Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 128: United Kingdom Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 129: Glance at 2010, 2015 and 2020 United Kingdom Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

FRANCE
Chart 130: French Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 131: Glance at 2010, 2015 and 2020 French Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 132: French Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 133: Glance at 2010, 2015 and 2020 French Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

ITALY
Chart 134: Italian Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 135: Glance at 2010, 2015 and 2020 Italian Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 136: Italian Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 137: Glance at 2010, 2015 and 2020 Italian Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

SPAIN
Chart 138: Spanish Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 139: Glance at 2010, 2015 and 2020 Spanish Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 140: Spanish Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 141: Glance at 2010, 2015 and 2020 Spanish Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

RUSSIA
Chart 142: Russian Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 143: Glance at 2010, 2015 and 2020 Russian Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 144: Russian Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 145: Glance at 2010, 2015 and 2020 Russian Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

REST OF EUROPE
Chart 146: Rest of Europe Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 147: Glance at 2010, 2015 and 2020 Rest of Europe Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 148: Rest of Europe Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 149: Glance at 2010, 2015 and 2020 Rest of Europe Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

ASIA-PACIFIC
Chart 150: Asia-Pacific Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 151: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 152: Asia-Pacific Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 153: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 154: Asia-Pacific Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 155: Glance at 2010, 2015 and 2020 Asia-Pacific Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 156: Asia-Pacific Erythropoietin Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 157: Glance at 2010, 2015 and 2020 Asia-Pacific Erythropoietin Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 158: Asia-Pacific Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 159: Glance at 2010, 2015 and 2020 Asia-Pacific Biotech Vaccines Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 160: Asia-Pacific Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 161: Glance at 2010, 2015 and 2020 Asia-Pacific Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 162: Asia-Pacific Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 163: Glance at 2010, 2015 and 2020 Asia-Pacific Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 164: Asia-Pacific Interferons Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 165: Glance at 2010, 2015 and 2020 Asia-Pacific Interferons Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 166: Asia-Pacific Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 167: Glance at 2010, 2015 and 2020 Asia-Pacific Human Growth Hormones (HGH) Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 168: Asia-Pacific Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 169: Glance at 2010, 2015 and 2020 Asia-Pacific Other Biopharmaceuticals Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 170: Asia-Pacific Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 171: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas
Chart 172: Asia-Pacific Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 173: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 174: Asia-Pacific Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 175: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 176: Asia-Pacific Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 177: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 178: Asia-Pacific Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 179: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 180: Asia-Pacific Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 181: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific
Chart 182: Asia-Pacific Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – Japan, China, India and Rest of Asia-Pacific in US$ Million
Chart 183: Glance at 2010, 2015 and 2020 Asia-Pacific Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – Japan, China, India and Rest of Asia-Pacific

JAPAN
Chart 184: Japanese Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 185: Glance at 2010, 2015 and 2020 Japanese Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 186: Japanese Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 187: Glance at 2010, 2015 and 2020 Japanese Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

CHINA
Chart 188: Chinese Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 189: Glance at 2010, 2015 and 2020 Chinese Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 190: Chinese Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 191: Glance at 2010, 2015 and 2020 Chinese Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

INDIA
Chart 192: Indian Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 193: Glance at 2010, 2015 and 2020 Indian Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 194: Indian Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 195: Glance at 2010, 2015 and 2020 Indian Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

REST OF ASIA-PACIFIC
Chart 196: Rest of Asia-Pacific Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 197: Glance at 2010, 2015 and 2020 Rest of Asia-Pacific Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 198: Rest of Asia-Pacific Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 199: Glance at 2010, 2015 and 2020 Rest of Asia-Pacific Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

SOUTH AMERICA
Chart 200: South American Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region - Argentina, Brazil and Rest of South America in US$ Million
Chart 201: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals Market Share (%) by Geographic Region - Argentina, Brazil and Rest of South America
Chart 202: South American Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 203: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 204: South American Monoclonal Antibodies (moAb) Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 205: Glance at 2010, 2015 and 2020 South American Monoclonal Antibodies (moAb) Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 206: South American Erythropoietin Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 207: Glance at 2010, 2015 and 2020 South American Erythropoietin Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 208: South American Biotech Vaccines Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 209: Glance at 2010, 2015 and 2020 South American Biotech Vaccines Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 210: South American Recombinant Human (RH) Insulin Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 211: Glance at 2010, 2015 and 2020 South American Recombinant Human (RH) Insulin Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 212: South American Granulocyte Colony-Stimulating Factor (G-CSF) Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 213: Glance at 2010, 2015 and 2020 South American Granulocyte Colony-Stimulating Factor (G-CSF) Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 214: South American Interferons Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 215: Glance at 2010, 2015 and 2020 South American Interferons Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 216: South American Human Growth Hormones (HGH) Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 217: Glance at 2010, 2015 and 2020 South American Human Growth Hormones (HGH) Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 218: South American Other Biopharmaceuticals Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 219: Glance at 2010, 2015 and 2020 South American Other Biopharmaceuticals Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 220: South American Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 221: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas
Chart 222: South American Biopharmaceuticals in Neurology Therapy Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 223: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Neurology Market Therapy Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 224: South American Biopharmaceuticals in Infectious Diseases Therapy Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 225: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Infectious Diseases Therapy Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 226: South American Biopharmaceuticals in Diabetes Therapy Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 227: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Diabetes Therapy Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 228: South American Biopharmaceuticals in Oncology Therapy Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 229: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Oncology Therapy Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 230: South American Biopharmaceuticals in Cardiovascular Therapy Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 231: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Cardiovascular Therapy Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America
Chart 232: South American Biopharmaceuticals in Other Therapeutic Areas Market Analysis (2010-2020) by Geographic Region – Argentina, Brazil and Rest of South America in US$ Million
Chart 233: Glance at 2010, 2015 and 2020 South American Biopharmaceuticals in Other Therapeutic Areas Market Share (%) by Geographic Region – Argentina, Brazil and Rest of South America

ARGENTINA
Chart 234: Argentine Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 235: Glance at 2010, 2015 and 2020 Argentine Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 236: Argentine Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 237: Glance at 2010, 2015 and 2020 Argentine Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

BRAZIL
Chart 238: Brazilian Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 239: Glance at 2010, 2015 and 2020 Brazilian Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 240: Brazilian Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 241: Glance at 2010, 2015 and 2020 Brazilian Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

REST OF SOUTH AMERICA
Chart 242: Rest of South America Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 243: Glance at 2010, 2015 and 2020 Rest of South America Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 244: Rest of South America Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 245: Glance at 2010, 2015 and 2020 Rest of South America Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

REST OF WORLD
Chart 246: Rest of World Biopharmaceuticals Market Analysis (2010-2020) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals in US$ Million
Chart 247: Glance at 2010, 2015 and 2020 Rest of World Biopharmaceuticals Market Share (%) by Product Segment – Monoclonal Antibodies (moAb), Erythropoietin, Biotech Vaccines, Recombinant Human (RH) Insulin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals
Chart 248: Rest of World Biopharmaceuticals Market Analysis (2010-2020) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas in US$ Million
Chart 249: Glance at 2010, 2015 and 2020 Rest of World Biopharmaceuticals Market Share (%) by Therapeutic Area – Neurology, Infectious Diseases, Diabetes, Oncology, Cardiovascular and Other Therapeutic Areas

Key Market Trends

The global economic downturn of the recent past has left the biopharmaceutical industry practically unscathed, with contractions and losses being negligible, thereby indicating that the industry is well on the track for full recovery and growth. Though the global economy is limping back to normalcy, the biopharmaceutical industry has remained dynamic and growing, with survey results indicating companies spending and investing greater amounts on R&D and bioprocessing capacities. The larger and well-entrenched companies have been adopting aggressive strategies aimed at cutting costs and enhancing efficiency, a trend which has proven to be of immense benefit to contract manufacturing and research organizations (CMOs and CROs). Though the earlier inclination towards cutting staff and divesting facilities has been on the decline, this could very well be a reflection of attaining limits of eliminating in-house expertise and facilities. A few of the major biopharmaceutical industry trends are enumerated as under.

Completion of Inspiration's Hemophilia Products Sale

Inspiration Biopharmaceuticals and Ipsen have completed the sale of all hemophilia assets of Inspiration including OBI-1 and IB1001. Inspiration and Ipsen have collaborated with Cangene Corporation, which would acquire the global rights to Inspiration's hemophilia B product, IB1001 (recombinant FIX), and also Inspiration's rights to IB1007 (recombinant FVIIa) and IB1008 (recombinant FVIII) by paying over US$300 million. Prior to this sale, Inspiration and Ipsen have completed the sale process of the former’s OBI-1 (recombinant porcine FVIII) to Baxter International for over US$700 million. OBI-1 and IB1001 are the key products of Inspiration developed to offer safe and efficient recombinant therapies to treat hemophilia patients worldwide. With the completion of this sale process, all hemophilia assets would be globally commercialized by Baxter and Cangene.

Novozymes Biopharma and EpiVax Ink Research Agreement

Novozymes Biopharma, part of Denmark-based Novozymes A/S, has inked a research agreement with EpiVax, Inc., a biotechnology company based in Rhode Island, United States, for advancing therapies of autoimmune diseases. Under this agreement, the proprietary Tregitope (T regulatory epitopes) immune-modulating therapy of EpiVax used in type 1 diabetes treatment would be integrated with the Albufuse half-life extension platform of Novozymes. This integration of technologies would develop a safe and efficient technology platform to utilize Tregitopes for multiple autoimmunity, transplantation and allergy conditions. This integrated platform would offer enhanced disease control by improving the overall treatment efficiency. The companies would advance the next stage development of autoimmune diseases treatment.

Glenmark Pharmaceuticals SA Discovers and Initiates IND Studies for GBR 830

Glenmark Pharmaceuticals Limited India's wholly owned subsidiary, Switzerland-based Glenmark Pharmaceuticals SA, has discovered and initiated investigational new drug (IND) enabling studies of a new clinical development candidate, GBR 830, an antagonistic mAb targeting OX40. La Chaux-deFonds, Switzerland-based Glenmark Biologics Research Centre has discovered and developed GBR 830. At present, no anti-OX40 antibodies exist in the clinical development stage. GBR 830 offers potential in being the therapeutic choice for treatment of immune pathologies such as autoimmune diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The discovery product line of the company would be enhanced by the antibody knowhow and production potencies of Glenmark Biologics Research Centre.

The material was prepared in July, 2013.

Skip to top

Genervon Biopharmaceuticals LLC - Product Pipeline Review - 2016 US$ 1,500.00 Dec, 2016 · 34 pages

Ask Your Question

Biopharmaceuticals - A Global Market Overview

Date:	July 15, 2013
Pages:	486
Price:	US$ 4,500.00
License [?]:
Publisher:	Industry Experts
Report type:	Strategic Report
Delivery:	E-mail Delivery (PDF)
ID:	B51C3190FDEEN
Leaflet:	Download PDF Leaflet
Sample:	Download Free Sample

Company name*:
Contact person*:
Phone/fax*:
Email*:
	Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: